Precise In Vivo Inflammation Imaging Using In Situ Responsive Cross‐linking of Glutathione‐Modified Ultra‐Small NIR‐II Lanthanide Nanoparticles

Zhao, Mengyao; Wang, Rui; Li, Benhao; Fan, Yong; Wu, Yifan; Zhu, Xinyan; Zhang, Fan

doi:10.1002/anie.201812878

Cited by 156 publications

(110 citation statements)

References 66 publications

(19 reference statements)

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3][4] Therefore, it requires effective imaging tools to assess the progression of diseases and their therapeutic response. [7][8][9][10][11] To date, compared to fluorescence imaging in the visible and nearinfrared wavelengths (<900 nm), deep tissue imaging in the second near-infrared window (NIR-II, 1000-1700 nm) has benefited from negligible tissue autofluorescence and scattering, leading to superior improvements in higher resolution and fidelity. [5,6] As a promising candidate of imaging modality with respect to noninvasive and nonradiation, optical imaging has been an area of intense focus in real-time visualization and monitoring the dynamic pathological processes of diseases.…”

Section: Introductionmentioning

confidence: 99%

Excretable Lanthanide Nanoparticle for Biomedical Imaging and Surgical Navigation in the Second Near‐Infrared Window

et al. 2019

Advanced Science

Self Cite

100

View full text Add to dashboard Cite

Recently, various second near-infrared window (NIR-II, 1000-1700 nm) fluorophores have been synthesized for in vivo imaging with nonradiation, high resolution, and low autofluorescence. However, most of the NIR-II fluorophores, especially inorganic nanoprobes, are mainly retained in the reticuloendothelial system (RES) such as the liver and spleen, leading to long-term safety concerns. Herein, a type of lanthanide-based excretable NIR-II nanoparticle, RENPs@Lips, which can be quickly cleared out of body after intravenous administration with half-lives of 23.0 h for the liver and 14.9 h for the spleen, is reported. Interestingly, over 90% of RENPs@Lips can be excreted through a hepatobiliary system within 72 h postinjection. The moderate blood half-time (T 1/2 = 17.96 min) allows for multifunctional applications in delineating the hemodynamics of vascular disorders (artery thrombosis, ischemia, and tumor angiogenesis) and monitoring blood perfusion in response to acute ischemia. In addition, RENPs@Lips exhibit high performance in identifying orthotopic tumor vessels intraoperatively and embolization surgery under NIR-II imaging navigation. Moreover, excellent signal-to-background ratio (SBR) is successfully achieved to facilitate sentinel lymph nodes biopsy (SLNB) with tumor-bearing mice. The high biocompatibility, favorable excretability, and outstanding optical properties warrant RENPs@Lips as novel promising NIR-II nanoparticles for future applications and translation into an interdisciplinary amalgamation of research in diverse fields.

show abstract

Section: Introductionmentioning

confidence: 99%

Excretable Lanthanide Nanoparticle for Biomedical Imaging and Surgical Navigation in the Second Near‐Infrared Window

et al. 2019

Advanced Science

Self Cite

100

View full text Add to dashboard Cite

show abstract

“…Other recent studies in this field include Zhao et al (2019) which reported on an original method for the accurate imaging of inflammation in vivo using in situ cross bonding of glutathione-combined ultrafine lanthanum nanoparticles with NIR-II fluorescent emission. Although nanoprobes have been proven to be promising bioimaging platforms by reason of their EPR effects, to the inability to enrich nanoprobe at target position has been a key bottleneck to improve detection ability and effect.…”

Section: Medical Testingmentioning

confidence: 99%

Recent Progress in NIR-II Contrast Agent for Biological Imaging

Cao

Zhu

Zheng

et al. 2020

Front. Bioeng. Biotechnol.

220

190

View full text Add to dashboard Cite

Fluorescence imaging technology has gradually become a new and promising tool for in vivo visualization detection. Because it can provide real-time sub-cellular resolution imaging results, it can be widely used in the field of biological detection and medical detection and treatment. However, due to the limited imaging depth (1-2 mm) and self-fluorescence background of tissue emitted in the visible region (400-700 nm), it fails to reveal biological complexity in deep tissues. The traditional near infrared wavelength (NIR-I, 650-950 nm) is considered as the first biological window, because it reduces the NIR absorption and scattering from blood and water in organisms. NIR fluorescence bioimaging's penetration is larger than that of visible light. In fact, NIR-I fluorescence bioimaging is still interfered by tissue autofluorescence (background noise), and the existence of photon scattering, which limits the depth of tissue penetration. Recent experimental and simulation results show that the signal-to-noise ratio (SNR) of bioimaging can be significantly improved at the second region near infrared (NIR-II, 1,000-1,700 nm), also known as the second biological window. NIR-II bioimaging is able to explore deep-tissues information in the range of centimeter, and to obtain micron-level resolution at the millimeter depth, which surpass the performance of NIR-I fluorescence imaging. The key of fluorescence bioimaging is to achieve highly selective imaging thanks to the functional/targeting contrast agent (probe). However, the progress of NIR-II probes is very limited. To date, there are a few reports about NIR-II fluorescence probes, such as carbon nanotubes, Ag 2 S quantum dots, and organic small molecular dyes. In this paper, we surveyed the development of NIR-II imaging contrast agents and their application in cancer imaging, medical detection, vascular bioimaging, and cancer diagnosis. In addition, the hotspots and challenges of NIR-II bioimaging are discussed. It is expected that our findings will lay a foundation for further theoretical research and practical application of NIR-II bioimaging, as well as the inspiration of new ideas in this field.Keywords: fluorescence imaging technology, the second region near infrared (NIR-II), biological imaging, contrast agents, biomedical applications Frontiers in Bioengineering and Biotechnology | www.frontiersin.org

show abstract

“…Wang et al. prepared NIR‐light‐responsive I/ D ‐Se‐NPs, and these polymers could form nanoscale micelles loaded with ICG and DOX (Scheme C) . Under λ =808 nm laser irradiation, the polymeric NPs were rapidly dissociated due to selenium oxidation caused by generated ROS.…”

Section: Stimuli‐responsive Drug‐release Nanosystemsmentioning

confidence: 99%

Strategies To Design and Synthesize Polymer‐Based Stimuli‐Responsive Drug‐Delivery Nanosystems

Qin

2020

ChemBioChem

View full text Add to dashboard Cite

The emergence and development of nanomedicine have alleviated problems existing in traditional chemotherapy drugs, such as short lifetime, concomitant side effects, and weak tumor‐targeting capability. Nevertheless, the further applications of drug‐loaded nanocarriers are still limited by their premature leakage, weak targeting capability, and insufficient intracellular release. In past decades, various nanocarriers, including gold nanoparticles, porous silica nanoparticles, carbon‐based nanoparticles, micelles, liposomes, and polymer–drug conjugates, have been intensively investigated for tumor therapy. Among these, polymer‐based nanocarriers have attracted more attention due to their biocompatibilities and capability of being modified for stimuli‐responsive drug release. In this review, three popular strategies to design and synthesize polymer‐based stimuli‐responsive nanocarriers are discussed. The discussion goes from stimuli‐responsive polymers with responsive backbones or modified by responsive functional groups for drug encapsulation and release to polymer–drug conjugates with responsive covalent linkages. In particular, due to the facile synthetic processes and mild reaction conditions for crosslinked structures, the latest progress in responsive crosslinked structures is emphasized. Finally, future perspectives for these nanomaterials are given, which are expected to provide inspiration for researchers to design more effective and safer tumor‐killing nanomedicines.

show abstract

Precise In Vivo Inflammation Imaging Using In Situ Responsive Cross‐linking of Glutathione‐Modified Ultra‐Small NIR‐II Lanthanide Nanoparticles

Cited by 156 publications

References 66 publications

Excretable Lanthanide Nanoparticle for Biomedical Imaging and Surgical Navigation in the Second Near‐Infrared Window

Excretable Lanthanide Nanoparticle for Biomedical Imaging and Surgical Navigation in the Second Near‐Infrared Window

Recent Progress in NIR-II Contrast Agent for Biological Imaging

Strategies To Design and Synthesize Polymer‐Based Stimuli‐Responsive Drug‐Delivery Nanosystems

Contact Info

Product

Resources

About